Agenus Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body’s immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
/ 
Others were interested in
See all stocksFrequently asked questions
To buy Agenus Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Agenus Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Agenus Inc. is AGEN:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Agenus Inc. has its primary listing on NASDAQ. You can trade Agenus Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Agenus Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Agenus Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Agenus Inc..